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The ubiquitin-proteasome system is the major intracellular molecular machinery for protein degradation and maintenance of
protein homeostasis in most human cells. As ubiquitin-proteasome system plays a critical role in the regulation of the immune
system, it might also influence the development and progression of multiple sclerosis (MS). Both ex vivo analyses and animal
models suggest that activity and composition of ubiquitin-proteasome system are altered in MS. Proteasome isoforms endowed
of immunosubunits may affect the functionality of different cell types such as CD8+ and CD4+ T cells and B cells as well as
neurons during MS development. Furthermore, the study of proteasome-related biomarkers, such as proteasome antibodies and
circulating proteasomes, may represent a field of interest inMS. Proteasome inhibitors are already used as treatment for cancer and
the recent development of inhibitors selective for immunoproteasome subunits may soon represent novel therapeutic approaches
to the different forms of MS. In this review we describe the current knowledge on the potential role of proteasomes in MS and
discuss the pro et contra of possible therapies for MS targeting proteasome isoforms.
1. Multiple Sclerosis and Proteasome Isoforms
Multiple sclerosis (MS) is a chronic disease of the central
nervous system (CNS) characterized by the presence of
inflammation, myelin damage, and axonal degeneration.
There are two main clinical courses of multiple sclerosis:
about 90% of MS patients experience the relapsing-remitting
MS phase (RRMS), characterized by disability episodes fol-
lowed by a complete or partial recovery. Multifocal lesions
are found by magnetic resonance imaging, typically but not
exclusively, in the white matter of the optic nerve, brain
stem, cerebellum, and spinal cord. Some lesions are enhanced
after intravenous administration of gadolinium, indicating
breakdown of the blood-brain barrier (BBB) as a result of
active inflammation. The majority of RRMS patients enter
into a secondary progressive phase (SPMS), characterized
by a variable degree of inflammation and a continuous and
progressive neurological decline in disability state (with or
without superimposed relapses) [1, 2]. A minor percentage
(10%) ofMS patients shows a primary progressive form ofMS
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(PPMS), characterized by progression of neurological dis-
ability from onset. Clinically relevant factors differentiating
RRMS and PPMS are age at disease onset (a decade later in
PPMS) and gender (1 : 1.3 male/female in PPMS versus 1 : 2 in
RRMS) [3]. Although the initial course of RRMS and PPMS
is very different, both proceed at remarkably similar rates
during the progressive phase. However, it is still an ongoing
debate whether the RRMS and the progressive forms of MS
are the same disease observed at different stages or whether
they are pathogenetically different.
One of the factors characterising MS is the autoimmune
response against self-antigens and the immune-mediated
demyelination which contribute, at least in part, to the
neurological manifestations. Based on scientific evidence, it
has been proposed that a predisposing genetic background,
in combination with environmental factors such as infection,
diet, sun exposure, and smoking, drives the immune system
tomount an immune response towards a yet unknownmyelin
antigen, eventually resulting inmyelin disruption [4]. Indeed,
genetic associations of HLA class II (HLA-DRB1∗15) and
HLA class I (HLA-A∗02, -A∗03, and -B∗07) with MS, as well
as the presence of autoreactive CD4+ and CD8+ T lympho-
cytes, together with other inflammatory cells and cytokines
in activeMS lesions, suggest an autoimmune pathogenesis [5,
6]. Several studies support the view that an immune response
in MS subjects starts and is maintained in the periphery,
and specifically in the lymphatic system, although the most
lethal cytotoxic effect occurs in the brain with oligodendro-
cytes, neuron loss, and plaque formation (outside-in model)
[2]. A competing view argues that the initial malfunction
occurs within the CNS, similarly to other neurodegenera-
tive diseases, by cytodegeneration, possibly focused on the
oligodendrocyte-myelin complex, and a release of highly
antigenic constituents that secondarily promote an autoim-
mune and inflammatory response in predisposed individuals
[2, 7].
In the last few years, additional players have emerged in
the MS pathogenic cascade, including proteasome and gut
microbiota (for the latter see Section 3). The proteasome is
the central catalytic unit of the ubiquitin-proteasome system,
which plays several crucial functions for cell metabolism
(Figure 1). By eliminating obsolete, misfolded, or aberrant
proteins, the ubiquitin-proteasome system accomplishes
housekeeping functions and maintains cellular homeostasis
and the physiological levels of intracellular proteins. It has
been demonstrated that proteasome inactivation leads to
cellular death by apoptosis or necrosis [8–10].The central role
of ubiquitin-proteasome system in inflammatory responses
is supported by evidence of its involvement in the on/off
switching of many cellular pathways through the time-
specific cleavage of short-life proteins, like transcription
factors ormolecules regulating the cell cycle [11]. Accordingly,
the proteasome is crucial in several inflammatory processes
by regulating cytokine signalling, cell proliferation, and
clearance of potentially deleterious products of inflammation
and is involved in the major histocompatibility complex
(MHC) class I-mediated antigen presentation (Figure 1) [12].
Therefore, proteasomemodulation can alter at different levels
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Figure 1: Schematic representation of the proteasome degradation
pathways.
both the physiological and pathological processes of the
immune system.
Different forms of proteasomes are known in eukaryotes.
They vary in terms of catalytic subunits and regulatory com-
plexes. The core 20S standard proteasome (s-proteasome)
is a cylinder-shaped complex, that is, composed of four
stacked rings, each consisting of seven protein subunits.
Among them the 𝛽1, 𝛽2, and 𝛽5 subunits harbour the
proteolytic active sites. The result of the association of the
20S proteasome core to the PA700 regulators is the 26S/30S
proteasomes, which cleave polyubiquitylated proteins in an
ATP-dependent manner. 20S proteasome can also bind the
PA28 regulator, which alters proteasome catalytic activities
[13, 14].
The immunoproteasome (i-proteasome) is an isoform of
the 20S proteasome. It carries specific catalytic subunits, that
is, 𝛽1i, 𝛽2i, and 𝛽5i (also known as LMP2, MECL-1, and
LMP7, resp.), which confer to the i-proteasome quantitative
differences in cleavage preferences and substrate degrada-
tion rates compared to the s-proteasome. I-proteasome is
generally synthesized upon interferon-𝛾 (IFN-𝛾) stimuli, but
tumor necrosis factor-𝛼 (TNF-𝛼) or lipopolysaccharide has
also been found to be involved in its inducible expression
[15, 16]. The vast majority of endogenous peptides that are
presented by theMHCclass Imolecules at the cell surface and
recognised by CD8+ T cells are generated by proteasomes.
I-proteasome is generally linked to its high efficiency in
the generation of the MHC class I-restricted epitopes. In
support of this, i-proteasomes are predominantly expressed
by professional antigen presenting cells (APCs), such as
dendritic cells (DCs) and B cells, or in other cell types during
inflammation, thereby indicating the i-proteasome as amajor
player of the MHC class I antigen presentation (Figure 1)
[11, 17].
Preliminary observations on white and grey matter of
MS patients suggested that the degradation rates of short
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fluorogenic peptides by 20S proteasomes are decreased when
compared to brain-tissue controls [18]. These results, how-
ever, cannot be interpreted as a general decrease of the
proteasome-mediated proteolytic activity, as recently shown
in [19–21]. Furthermore, an accumulation of i-proteasome
and its regulator PA28𝛼𝛽 has been observed in differ-
ent cell types affected by MS, such as oligodendrocytes,
astrocytes, macrophages/microglia, infiltrating lymphocytes,
and weakly neurons [22]. Such disease-related expression of
i-proteasome is in agreement with recent observations in the
experimental model of MS, that is, the experimental autoim-
mune encephalomyelitis (EAE). In this model, the cerebral
expression of i-proteasome and PA28𝛼𝛽 was increased as
compared with baseline levels during the acute phase of
EAE. Of note, i-proteasomes were also detected in neurons,
infiltrated T lymphocytes, and microglia in EAE mice [23].
However, in this study by Zheng et al., an equal expression of
s- and i-proteasome subunits has been described in control
mouse brain, contrasting with other studies on rodents and
humans which reported a faint expression of i-proteasome
in young/adult brains [21, 24, 25]. Furthermore, Zheng et al.
reported no differences in the i-proteasome expression by
comparing young and old control mouse brains, which is in
contrast to studies on other mammals such as rats [21, 26]
and humans [27], but in agreement with a study conducted
on nonhuman primates [28].
The expression of i-proteasome in MS lesions or in
cells involved in MS mechanisms is important because this
isoform has been recently linked to different inflammatory
processes. Indeed, i-proteasomes are specifically implicated
in cytokine-mediated inflammation, cell growth, and differ-
entiation in mice [11]. I-proteasome depletion alters the T
cell antigen receptor (TCR) repertoire formation, the number
and differentiation of CD8+ T cells, and the production of
proinflammatory cytokines [29]. In addition, i-proteasome
depletion during IFN-𝛾-mediated oxidative stress is con-
sistent with a deficient clearance of oxidized proteins and
aggresomes [30, 31]. These events have been associated with
worsening of EAE clinical score in𝛽5i−/−mice [31], although
discordant results have also been reported by others [32].
In the following sections we will discuss these and
additional data suggesting an involvement of proteasomes in
specific pathways underlying MS.
2. I-Proteasome and CD8+ T Cells in MS
CD4+ and CD8+ T lymphocytes reactive against myelin have
been found in peripheral blood, cerebrospinal fluid (CSF),
and CNS plaques of MS patients, but their role in MS
pathogenesis is still a matter of debate. Antimyelin CD4+
T cells in MS have been widely studied because of their
role in regulating cell-mediated inflammation, their ability in
inducing EAE, and the identification of HLA-DRB1∗15 allele
as the most significant genetic risk factor associated with
MS [33]. EAE can also be triggered by the administration
of CD8+ T cells specific against myelin antigens in mice.
In MS, CD8+ T cells exceed CD4+ T cells by 3–10-fold in
regions of demyelination, and the degree of axonal damage
withinMS lesions correlates with the number of CD8+ T cells
[33]. Furthermore, several studies described an increased
prevalence of CD8+ cytotoxic T cells reactive against specific
myelin epitopes in peripheral blood ofMS patients compared
to healthy controls [34–36]. These observations, in addition
to the genetic associations of HLA class I alleles withMS risk,
suggest an involvement of CD8+ T cells in MS [33].
Because i-proteasome is a major player in the processing
of MHC class I-restricted epitopes in professional APCs or in
inflamed conditions, it is likely that it is also involved in the
presentation ofmyelin antigens in theMS brain. For instance,
i-proteasome expression is induced in oligodendrocytes of
MS patients [22]. These cells are the main producers of
myelin, and hence likely to be the target of CD8+ T cells in
MS. Indeed, CD8+ T cells were observed in close proximity
to oligodendrocytes and demyelinated axons in brain tissue,
towards which cytolytic granules were polarized [33]. The
expression of i-proteasome in oligodendrocytes might there-
fore alter the presentation onto the MHC class I molecules of
myelin antigens and the cytotoxic activity of specific CD8+ T
cells towards these cells.
Although the abovementioned scenario lacks experimen-
tal validation, there is substantial support for this theory.
For instance, our group has previously observed in vitro
that i-proteasome carrying a polymorphic variant at codon
60 (i.e., HH60) of 𝛽1i subunit produces less amount of the
myelin basic protein epitope MBP
111−119
[22]. This epitope
is presented on the HLA-A∗02 molecule, although with
moderate affinity [22] and memory CD8+ cytotoxic T cells
specific for this epitope are more prevalent in the blood of
MS patients than controls [35–37]. We also described a lower
prevalence of the 𝛽1i HH60 variant among MS females with
HLA-A∗02+ genotype when compared to a matched control
population.These observations led us to hypothesize that the
lower risk of developing MS in HLA-A∗02+ subjects carrying
the 𝛽1i HH60 variant could be—at least in part—due to
a lower production of MBP
111−119
by oligodendrocytes or
APCs in these subjects [22].
The key role of i-proteasomes in autoreactive CD8+ T
cell response has been recently confirmed by the observation
that mice lacking i-proteasome 𝛽5i-𝛽2i subunits developed a
multitissue autoimmune disorder mediated by CD8+ T cells
via altered MHC class I-restricted self-antigen presentation
[38].The authors of the study speculated that a relatively high
percentage of MHC class I molecules present “dangerous”
epitopes in presence of inflammation and in the absence
of i-proteasome. These self-peptides are low-affinity binders
to the MHC class I complexes (as the epitope MBP
111−119
[22]) and are better produced by s-proteasomes. Hence, in
the absence of an appropriate i-proteasome activity these
“dangerous” self-epitopes may be generated and targeted by
autoreactive CD8+ cytotoxic T cells, thereby triggering an
autoimmune response [38]. It is attractive to hypothesize that
a similar mechanism is at work in MS and would imply that
i-proteasomemight hamperMSdevelopment by reducing the
amount of “dangerous” self-peptides presented by APCs in
periphery.
Another matter of debate relies on the mechanisms
causing the disruption of the immune system tolerance and
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the activation of autoreactive CD4+ andCD8+ T lymphocytes
towards CNS cells. Different studies suggest that molecular
mimicry could be involved in the immune system disruption.
This phenomenon describes the reaction of a single T cell
clone to epitopes derived from both pathogen and human
proteomes. It has been proposed that MS is triggered by a
viral infection that, in the presence of (unknown) additional
environmental and genetic factors, leads to an uncontrolled
activation of autoreactive T cells. Such theory could explain
in part the geographic distribution of the risk of developing
MS [4] and is supported by several studies showing an
increase of EBV-specific cellular immune responses in the
blood and in theCSF of subjects withMS [5, 39–42], although
the association with other viruses has also been found [4].
Conflicting results however exist about the role of molecular
mimicry in driving pathological disorders associated with
CD8+ T cells, as a comprehensive analysis on a broad range of
CD8+ cytotoxic T cell clones showed a very limited number of
cross-reactive T cells recognising both viral and self-epitopes
[43].
The mechanisms of molecular mimicry related to CD8+
T cells in autoimmune disorders could be further investi-
gated bearing inmind another proteasome-mediated process,
named proteasome-catalyzed peptide splicing (PCPS). PCPS
occurs through the binding of separate peptide fragments
originating from a single protein, that is, cis-PCPS, or
from two distinct protein segments, that is, trans-PCPS
(Figure 2) [44–46]. The role of PCPS in MS has not been
investigated yet, although it might be relevant for several
reasons. Firstly, PCPS is more prone to generate MHC class
I-restricted potential epitopes than the simple proteasomal
peptide hydrolysis because of specific biochemical features of
PCPS [47]. In addition, PCPS highly increases the diversity of
MHC class I-restricted epitopes from self- and viral-antigens
as the number of potential peptides presented on MHC
molecules is several times higher than the number of peptides
encoded in the proteome [48]. Consequently, through the
PCPS there could be a significant increase of MHC class
I-restricted epitopes with high sequence homology to viral
and human proteomes. This phenomenon implies that the
activation of CD8+ T cells specific for “spliced” viral epitopes
with high or even complete homology with myelin antigens
could represent a threat against myelin-producing cells and
eventually take part in the development of MS.
3. Th17 Cells, Gut Microbiota, and
Proteasome in MS
CD4+ T cells become activated by recognising antigens
presented onto the MHC class II molecules, which are only
expressed on professional APCs (such as DCs, macrophages,
and B cells). Upon antigen stimulus, CD4+ T lymphocytes
differentiate into two main subpopulations, T helper type 1
(Th1) cells and T helper type 2 (Th2) cells. Activated CD4+ T
cells can also differentiate into regulatoryT (Treg) cells, which
are characterised by the expression of the forkhead box P3
(FoxP3) transcription factor [49].
R T K A W N R Q L Y P E W
Thr1Thr1
Proteasome proteolytic subunits
R T K Q L Y P E W Q L Y P E W Q L Y P E W
trans-PCPScis-PCPS
Figure 2: Proteasome-catalyzed peptide splicing (PCPS). PCPS
can occur by ligation of two fragments of the same substrate
molecule (cis-PCPS) or derived from two distinct protein molecules
(trans-PCPS). Shown here are the representative cleavages (depicted
by dotted lines) of the peptide gp100
40−52
(sequence: RTKAWN-
RQLYPEW) by two distinct proteasome catalytic subunits, which
generate the fragments RTK, AWNR, and QLYPEW. According to
the PCPS model [44, 47], the protein is first cleaved by the active
site residue Thr1 of the proteasome proteolytic subunits, thereby
producing a protein fragment. The latter peptide stays attached to
the catalytic centre where, subsequently, it is ligated to a second
peptide generating the proteasome-generated spliced peptide.
More recently, a new T cell subpopulation, theTh17 cells,
which secretes IL-17, IL-21, and IL-22, has been described
and associated with the control of extracellular pathogens
[50]. Th17 cells and their cytokines are associated with
several autoimmune and inflammatory diseases, such as
rheumatoid arthritis, systemic lupus erythematosus, MS,
psoriasis, inflammatory bowel disease, allergy, and asthma
[51]. In MS patients, IL-17 expression is increased in blood
mononuclear cells and in CSF as well as at the site of
lesions [52]. IL-17 and IL-22 promote blood-brain barrier
permeability and CNS inflammation by inducing chemokine
production in endothelial cells and by downregulating tight
junction proteins. IL-17 also stimulates astrocytes to produce
CXC chemokines that can attract neutrophils to the BBB and
activate them to release vasoactive substances [53]. It has been
shown that myelin-specific Th17 cells directly interact with
neuronal cells in demyelinating lesions [54]. Either deficiency
or neutralization of IL-17 delay the onset and reduce the
severity of EAE [55]. Furthermore, IL-23 expands Th17 cells
and is critical for the induction of EAE. In contrast, a recent
paper reported that overexpression of IL-2 in vivo reverses
EAE pathology by decreasing the Th1 and Th17 infiltration.
Notably, under inflammatory conditions (such as in EAE),
Th17 cells display plasticity because these cells can change
phenotype in inflamed tissues and secrete proinflammatory
cytokines such as IFN-𝛾 instead of IL-17 [56].
A modifier ofTh17 cell response in MS may be gut bacte-
ria, which play an important role in shaping intestinal CD4+
T cell responses [57] and in affecting brain inflammation, as
suggested by evidence on gut-brain communication [58, 59].
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The mammalian gastrointestinal track harbors a highly het-
erogeneous population of microbial organisms, which vary
across geographical areas and are essential for the complete
development of the immune system. The gut microbes or
“microbiota” also drive a swarm of T cell responses in the
gut. For instance, segmented filamentous bacteria trigger
intestinalTh17 cell responses; indeed when these bacteria are
used to monocolonize germ-free mice they restore Th17 cell
responses in the lamina propria of the small intestine [60].
Gut bacteria are also critically involved in the differentiation
of some Treg cell subsets [61] as these specific microbial
organisms have developed distinct ways to promote effector T
cells or Treg cell differentiation in the gut [62].The Treg/Th17
ratio and also the Treg cell frequency have been negatively
correlated with MS severity [63], thereby suggesting that the
measure of their balance could be an informative biomarker
for evaluating or comparing the effectiveness ofMS therapies.
In the context of MS models, it has been reported
that the treatment of EAE mice with probiotics reduces
neuroinflammation [64] and that different gut microbiota
could induce [34, 65] or tackle CNS inflammation [66]. In
addition, antibiotic-mediated depletion of the gut microbiota
reduces the EAE severity and the levels of proinflammatory
cytokines and chemokines, whereas it increases the levels of
the anti-inflammatory cytokines IL-10 and IL-13. Moreover,
IL-10-producing FoxP3+ Treg cells accumulate in the cervical
lymph nodes of antibiotic-treated mice and protect naı¨ve
recipients against the transfer of EAE [65].
The tight connection between commensal gutmicrobiota,
EAE, andTh17 lymphocytes has been recently investigated in
two different models of EAE. Lee and colleagues [67] studied
the induction of EAE by immunizing germ-free bacteria,
specific-pathogen-free and control mice with MOG
35−55
peptide + Mycobacterium tuberculosis. They observed that
germ-free mice are highly resistant to EAE development and
have a lower prevalence of Th17 and Th1 cells leading to the
conclusion that there is a hampering of the systemic and neu-
ronal proinflammatoryTh17 andTh1 response during EAE in
absence of commensalmicrobiota inmice.This phenomenon
seems to be reversible because intestinal colonization with
segmented filamentous bacteria in germ-free mice promotes
EAE development. They concluded that the microbiota
dynamically and reversibly impacts the programming of
pathogenic immune response during autoimmunity and that
microbial colonizationmay provide proinflammatory signals
that affect the reciprocal development of Th and Treg cells
both in gut and in CNS [67].
In a second article, Berer and colleagues [68] reported
that germ-free mice develop less frequently EAE, a phe-
nomenon accompanied by a reduced number ofTh17 cells in
the lamina propria and reduced secretion of IL-17 and IFN-𝛾
by splenic T cells in response to cognate antigen stimulation.
In this latter study, a spontaneous remitting-relapsing EAE
mouse model has been used. These mice express, in a large
proportion of their CD4+ T cells, a transgenic TCR that
recognizes MOG
92−106
peptide in the context of MHC class
II molecules [68]. The fact that two independent studies
described, in different models of EAE, an impairment of
Th17-mediated induction of EAE in germ-free mice supports
the hypothesis that gutmicrobiotamay influenceMS viaTh17
cell activity.
Another modifier of the Th17 cell response in MS may
be the i-proteasome. Indeed, it has been shown that the in
vitro administration of i-proteasome 𝛽5i subunit inhibitor
prevents the early activation of CD4+ T cells, their differentia-
tion intoTh17 cells, and the secretion of TNF-𝛼, IL-23, and IL-
6 [69]. In vivo, 𝛽5i inhibition or deficiency results in reduced
Th1 and Th17 cell expansion and Treg cell development
through STAT3/STAT1/SMAD phosphorylation [70]. The
treatment with 𝛽5i subunit inhibitor also attenuates the pro-
gression of the experimental arthritis in mice [69]. Because
this phenomenon acts on the Th17 differentiation pathway
and it is not observed by inhibiting s-proteasome activity,
we may speculate that a selective block of i-proteasome 𝛽5i
subunit in mice might also tackle the development of EAE.
Preliminary evidence in dextran sodium sulfate-induced
colitis indirectly support such speculation, since this animal
model mimics inflammatory bowel diseases, such as Crohn’s
disease and ulcerative colitis, which are characterized by a
marked mucosal infiltration of T cells that secrete Th1 and
Th17 cytokines and alterations of faecal andmucosal bacterial
communities [71]. Interestingly, in 𝛽5i subunit −/− mice
and in wild type mice treated with a proteasome inhibitor,
there is a reduction in the secretion of proinflammatory
cytokines and chemokines, the infiltration into the colon by
neutrophils, and the expansion ofTh1 andTh17 cells, thereby
preventing excessive tissue damage [72]. These observations
are in agreement with the results of Basler et al. [73],
which showed a role of 𝛽5i subunit inhibition in reducing
the production of proinflammatory cytokines, inflammation,
tissue destruction, and consequently pathological symptoms
of experimental colitis.
These data suggest that in EAE the activity of Th17 cells
could be regulated by gut microbiota and i-proteasomes.
Therefore, both of them may be potential targets for the
treatment of MS, although there are no studies that inves-
tigated the direct interaction between gut microbiota and
i-proteasome in EAE.
4. Humoral Immunity, Proteasomes, and MS
The understanding of MS pathogenesis has been mostly
driven by studies on T cells and their inflammatory cytokines
produced in damaged tissues [74]. The interest regarding the
antibody-dependent as well as antibody-independent B cell
involvement has received a strong boost from the success of
clinical trials targeting B cells in MS and other autoimmune
diseases [75, 76].
Beyond their ability to produce antibodies, B cells func-
tion as APC, thereby contributing to T cells activation in
the CNS [77]. They also influence the immune response
through the production of effector cytokines, such as those
involved in immune regulation (e.g., anti-inflammatory IL-
10), polarization (IL-4), and cytokines involved in lymphoid
tissue organization (e.g., TNF-𝛼 and leukotrienes) [78].
Remarkably, decreased levels of IL-10 and increased concen-
trations of TNF-𝛼 and leukotrienes have been described in
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patients affected by MS [79], thus contributing to abnormal
T-cell activation.This fact provides a conceivable mechanism
of action to explain why B cell depletion may be relevant,
both in the periphery and in the CNS, in diminishing new
MS activity [79]. Indeed, Rituximab, a monoclonal antibody
against CD20 molecules, exerts its therapeutic effect through
a rapid and profound depletion of peripheral B cell, along
with a significant reduction in the volume of T2 lesions and
clinical relapse in the RRMS patients, and a reduced disease
progression in PPMS [80, 81]. Additionally, in a small cohort
of PPMS, it has been shown that Rituximab temporarily
suppresses the activation of B cells in CSF [82]. However, the
presence of regulatory B cell subsets (B regs), which could
either induce or inhibit immune response, accounts for the
variable effects that targeting B cellsmay have in vivo [77–80].
At present, new monoclonal antibodies (i.e., Ocrelizumab,
Ofatumumab) targeting CD20 or specific surface markers of
B cell subset (i.e, Atacicept) are under investigation in phase
II/II trials [83, 84].
Although at present there is no data available on pro-
teasome isoforms, B cell regulation, and MS, the recent
observation of Hensley et al. [85] is relevant to connect
all these three topics. Indeed, the authors reported that i-
proteasome 𝛽1i subunit −/− mice have a defect in B cells
maturation and Ig isotope switch upon viral infection as well
as in CD4+ T cell survival and DC activation.They identified
in the NF-𝜅B activation one of the pathways affected by the
presence of intermediate type proteasomes instead of the
i-proteasome, which is normally present in these cells. A
role of i-proteasome inmodulating NF-𝜅B signalling has also
been observed by Maldonado and coworkers [86] in retinal
pigment epithelial cells of 𝛽1i subunit −/−mice. In knockout
mice a higher content and a diminished activation of the
NF-𝜅B alternative pathway, as well as a delayed termination
of the classical pathway, after in vitro stimulation by TNF-𝛼,
has been observed compared to wild type littermates [86].
Concerning the role and significance of antibodies in MS
patients, the presence of CSF oligoclonal bands and increased
immunoglobulin IgG synthesis is a frequent feature of MS
[87] as well as other localized autoimmune diseases of the
CNS [88]. These pathogenic autoantibodies (autoAbs) can
induce tissue damage and thus be involved in plaque initi-
ation and demyelination by recruiting macrophages and by
complement deposition in white matter lesion of MS patients
[89]. However, the antigenic targets of these antibodies and
their potential use as biomarkers of MS are still a matter
of debate. Indeed, autoAbs against antigens not specific for
the CNS have also been associated with MS, although it
is unclear if they are pathogenic effectors instead of being
secondary products of the release of antigens upon CNS
tissue damage. Proteasome Abs, for example, are elevated
in sera of RR-, PP-, and SP-MS patients compared to other
autoimmune diseases or healthy controls [90–92]. It has been
shown in vitro that autoAbs against 20S proteasome block the
proteasome activation by PA28 regulator, thereby suggesting
that these autoAbs might have a regulatory function towards
extracellular proteasomes such as circulating proteasomes
[93]. Notably, although proteasomes are mainly studied as
intracellular proteases, extracellular circulating proteasomes
are normally present in peripheral blood, and their lev-
els are significantly increased in a variety of pathological
conditions, including autoimmune diseases and tumours
[94]. In particular, as biomarkers of ongoing pathological
mechanisms, circulating proteasomes have demonstrated to
have prognostic power as regards therapy outcome and
survival in multiple myeloma patients [95]. Although cells
originating extracellular proteasomes detected in peripheral
blood and in the CSF have not been identified, an active
release of circulating proteasomes has been recently proposed
[96] as they have been copurified with exosomes [97]. In
line with this hypothesis, the immunological activity rather
than the cellular damage has been suggested as the causative
mechanism for increased circulating proteasome levels in
sepsis and sever injury [98]. Recently, a preliminary study
carried out on a limited number of patients affected by RRMS
has shown that circulating proteasome amount increases in
MS and even further in MS patients treated with IFN-𝛽. The
authors have also described a specific proteasome activity pat-
tern in plasma ofMSpatients although they have not reported
appropriate control experiments with proteasome inhibitors
[99]. This preliminary observation, however, might be rele-
vant for future studies. Indeed, a fascinating speculation is
that circulating proteasomes in peripheral blood are not only
simple biomarkers of inflammatory status, but also active
proteases that might control cytokine levels, cell-mediated
cytotoxicity, and plasma membrane permeability [94] and
synergize with other component to ameliorate tissue damage
[97].
5. Maintenance of Cellular Homeostasis
during Inflammation-Mediated Oxidative
Stress in MS
The pathological mechanisms of neurodegeneration,
although largely unknown, are often mediated by oxidative
stress and excitotoxicity (degenerative cascade), two
processes that are closely interactive [100, 101]. The
increased production of reactive oxygen and nitrogen species
induces oxidative damage to different cellular components
including lipid, DNA, and proteins [102]. Accordingly,
in MS patients, oxidized DNA is present in a small
number of reactive astrocytes as well as in oligodendrocyte
nuclei, with evidence of apoptosis [103]. Similarly, lipid
peroxidation-derived structures (malondialdehyde and
oxidized phospholipid epitopes) can be detected in the
cytoplasm of oligodendrocytes and some astrocytes as well
as in degenerating neurons within grey matter lesions [103].
Oxidized proteins are more prevalent in cerebellar astrocytes
as well as in spinal cord neurons of EAE mice [104, 105].
In such scenario, an effective removal of oxidized proteins
seems to be a key element to maintain cellular homeostasis
during neuroinflammation.
Studies performed on neuronal cell lines have sug-
gested that proteasome plays a central role in mitochondria
homeostasis. Proteasome inhibition decreases the activity
of complexes I and II and increases the production of
reactive oxygen species and the accumulation of lipofuscin,
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a highly oxidized cross-linked aggregate of oxidized protein
and lipid [106, 107]. In addition, proteasome is essential in
maintaining cell homeostasis by degrading obsolete, dam-
aged, and oxidized proteins [108–112]. Notably, the 20S
proteasomes are more resistant to oxidative stress than 26S
proteasomes and seem to be able to degrade oxidized proteins
in an ATP-independent manner [113, 114]. Furthermore,
i-proteasome expression is induced during oxidative stress
in several inflammatory-based diseases in the CNS and in
peripheral organs [30, 115, 116] and it provides enhanced
cellular resistance to oxidative stress, at least in part by an
increased degradation rate of oxidized proteins compared
to s-proteasome [117]. Indeed, the blocked expression of 𝛽1i
subunit by siRNA significantly reduces the adaptive response
to mild oxidative stress in mouse embryonic fibroblasts [116],
𝛽5i-depleted retinal pigment epithelial cell viability is more
compromised than wild type cells [30], and 𝛽1i subunit −/−
mice exhibit higher levels of protein carbonyls in brain and
liver upon aging than those of their wild type littermates
[118]. Accordingly, Seifert and coworkers [31] have shown
an accumulation of oxidized and polyubiquitylated proteins
and aggresome-like induced structures upon INF-𝛾 stimuli
in the liver and brain of i-proteasome 𝛽5i subunit −/− mice.
Moreover, 𝛽5i subunit deficient cells and tissues are not only
more sensitive to apoptosis but also have a delayed activation
of NF-𝜅B after TNF-𝛼 stimulation [31]. This dependence of
protein oxidation clearance on i-proteasome activity might
be pivotal forMS because i-proteasome 𝛽5i subunit −/−mice
showed an earlier onset and worse clinical score than wild
type mice in an EAE model [31] although this fact, recently,
has been disputed by Nathan and colleagues [32].
Overall, these results suggest that i-proteasomes may
influence onset and progression of MS by affecting the
response of different cell types to the inflammatory aggres-
sion in the CNS.
6. Is Proteasome Inhibition a Potential
Therapy of MS?
The administration of immunomodulatory drugs (glatiramer
acetate and IFN-𝛽) represents the first line therapy for RRMS,
but these drugs are seldom useful towards the progressive
form of MS [119]. The partial or total inefficacy of the com-
mon MS treatments in SPMS and PPMS patients demands
the identification of novel therapies. The progressive forms
of MS seem to be characterized by peculiar immunological
mechanisms that differ from RRMS. In PPMS and SPMS the
whole brain is affected and inflammation as well as axonal
injury is diffuse, whereas in RRMS inflammation and tissue
damage aremore focalized in plaques [120]. In the progressive
forms ofMS, the CD4+ and CD8+ T cells and the B cells seem
to be part of the pathological mechanisms, although with
characteristics that differ from those observed in RRMS and
without a clear correlation between immune cell activation
and clinical measures of disease duration and severity, espe-
cially in PPMS [121]. Considering the complex pathogenic
mechanisms at the basis of MS development, further studies
would be needed to better characterize the role of different
immune system players, including proteasomes, autoAbs as
well as specific Th17 and CD8+ T cells, in the different forms
ofMS.These studies are likely to support the discovery of new
diagnostic and prognostic biomarkers for different MS forms
and to generate novel therapeutic drugs such as the specific
proteasome inhibitors. Indeed, proteasome inhibitors have
been utilised as therapeutic approach towards other diseases,
such as multiple myeloma, and selective inhibitors for s- or
i-proteasome have been recently developed [122].
Two factors could influence the success of novel therapies
based on proteasome inhibitors: their toxicity profiles and
their delivery pathways to the CNS and/or the periphery.
Regarding the former, the experience of the first proteasome
inhibitor, named Bortezomib, approved for clinical treatment
of hematologic malignancies, showed that the toxicity could
be a limiting factor [122]. However, this disadvantage can
be controlled with new inhibitors specific for i-proteasome
subunits that can therefore block proteasome activity only in
specific cells or pathological conditions [122]. In such contest,
the induction of i-proteasome expression in specific cell types
upon MS onset—reviewed in Section 1—is a pivotal element
ought to be borne in mind.
An additional critical issue is drug delivery. Indeed,
the inhibition of i-proteasome is detrimental in tackling
the oxidative stress during inflammation, leading to the
accumulation of oxidised proteins [11]; this has been linked
to the disputed observation that the depletion of 𝛽5i subunit
anticipated EAE onset [31, 32] (Table 1). However, further
investigations have to be performed since the blockage of
i-proteasome activity resulted in a decreased expression of
inflammatory biomarkers in ex vivo analyses of microglia
of a mouse model of Alzheimer’s disease [19]. Conversely,
an inhibition of i-proteasomes limited to the periphery and
towards immune system components such as B andTh17 lym-
phocytes might be beneficial in treating MS. Noteworthy, the
promising results of the clinical trials with the monoclonal
antibody Rituximab for the treatment of MS (see Section 4)
are consistent with the hypothesis that also a depletion of B
cells might ameliorate MS disease. In mice, such depletion
could be achieved by a defect in 𝛽1i subunit expression [85]
(Table 1).
Furthermore, Th17 cells could be targeted for amelio-
rating MS course. As i-proteasome inhibition decreases the
activation of Th17 cells in mice [69, 70], it can be envisaged
that i-proteasome inhibitors could be used to limit Th17 cell
activation and EAE progression in mice (Table 1). The first
test of this hypothesis could be obtained by treating EAE
mice with inhibitors of the i-proteasome 𝛽5i subunit, as it has
been already done for other experimental diseasemodels [69,
73]. Notably, a blockage of the i-proteasome activity along
the Th17 cell pathway could be coupled to the therapeutic
administration of probiotics (live beneficial bacteria) or
prebiotics (compounds that stimulate the growth of beneficial
bacteria) in EAE mice, given their common action on Th17
lymphocytes [67, 68]. Nonetheless, whether the modulation
of gut microbiota could have similar beneficial effects also on
MS is largely unknown. In EAE, the depletion or the strong
modification of gut microbiota showed beneficial effects on
the development of the disease [67, 68]. However, unlike
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Table 1: Proteasome isoforms as potential targets of immunological pathways. The table summarizes the major results that may help future
studies to understand how the inhibition of distinct proteasome isoforms may affect the development and progression of MS.
Final targetsa Anatomic area Proteasome subunits inhibitedb MS forms Potential effectsc References
CD8+ T cells Thymus, lymph nodes, CNS 𝛽1i, 𝛽2i, 𝛽5i NA +/− [22, 29, 38, 123,124]
CD4+ Th17 cells Thymus, lymph nodes, CNS, gut 𝛽1i, 𝛽2i, 𝛽5i NA + [51, 67, 68, 70,72, 73]
B cells Thymus, lymph nodes, CNS 𝛽1i RR, PP, SP + [80, 81, 85]
Proteasome Abs Serum NA RR, PP, SP NA [90]
Circulating
proteasome Serum NA NA NA [94, 99]
CNS parenchyma CNS 𝛽5i NA − [31]
aPathways that are directly or indirectly affected by treatment with proteasome inhibitors; bevidence from studies where the inhibition/depletion of specific
proteasome subunit provided hints about their potential effect on MS; cthese effects also include speculative arguments on how the proteasome subunit
inhibition may affect specific pathways. The detrimental or beneficial effects are marked as “−” or “+,” respectively; NA = not available evidence.
mouse models, the human being has a broad variety of
diet, environment, genetics, and early microbial exposure
features that lead to highly diversified microbiota, which
is furthermore extremely adaptable and variable over time
[125, 126]. Therefore, the identification of a beneficial or
detrimental microbiota towards MS might be strenuous.
While the potential inhibition of i-proteasome activity in
B and Th17 cells points towards a beneficial effect against
MS, the knowledge of the role of circulating proteasome
and of proteasome Abs remains poor. Because of high
levels of circulating proteasomes and proteasome Abs in
the serum of MS patients [90, 99] a tempting speculation
is that the production of proteasome Abs might aim to
affect the circulating proteasome activity, although the role
of circulating proteasomes in MS and more in general in the
peripheral blood is largely unknown (Table 1). Further studies
are mandatory to investigate such an issue because a therapy
with proteasome inhibitors delivered through peripheral
blood would immediately affect circulating proteasomes.
The potential effects of an i-proteasome inhibition within
the CD8+ T cell-mediated immune response are still unclear.
This inhibition could affect therapy outcome depending on
whether the drug is delivered in the periphery only or
also in the CNS. Indeed, i-proteasome could influence the
presentation of endogenously produced myelin antigens in
oligodendrocytes (i.e., in CNS) and in bone marrow-derived
APCs (i.e., in periphery) [123, 127], although the outcome of
the activation of antimyelin CD8+ T cells is still a matter of
debate. For instance, in transgenic mice the induction of EAE
by HLA-A∗03-restricted myelin epitope was hampered by
the overexpression of HLA-A∗02 molecules, confirming the
opposite (and interacting) action of MHC class I-restricted
myelin epitopes on EAE onset [124]. Furthermore, it has
been hypothesized that the expression of i-proteasome limits
the generation of self-epitopes associated with autoimmune
responses [38] and we have proposed that a link exists
between a genetic protection towardMS and an i-proteasome
polymorphism that impairs the generation of a specific MBP
epitope [22].We therefore conclude that i-proteasomes could
play a role in the CD8+ T cell-mediated immune response in
MS, and further studies shall better define the role of CD8+
T cells in this pathology and identify which epitopes trigger a
deleterious autoimmune CD8+ T cell reaction and how they
are generated by different proteasome isoforms.
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